Back to search results

Observational Study of Clear Cell Carcinoma of the Cervix

This observational study is looking at clear cell carcinoma of the cervix, a type of cervical cancer not linked to Human Papillomavirus (HPV). Researchers will review medical records and analyze tissue samples from patients diagnosed and treated for this condition at MD Anderson Cancer Center. The goal is to understand more about the features of this cancer, including its molecular profile (the specific genetic and protein characteristics). This information could help doctors learn more about this rare cancer. This study plans to include 70 women.

Study design
This is an observational study, meaning researchers will look at existing medical information and tissue samples. It plans to include 70 participants.
What's involved
Your medical records will be reviewed, and archival tumor tissue will be analyzed. You will not undergo any new procedures or tests for this study.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, a clinicopathologic study, will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Recruiting
Not specifiedAll AgesObservational
M.D. Anderson Cancer Center
~70 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Electronic Health Record ReviewLaboratory Biomarker Analysis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix
Measured over through study completion, an average of 1 year

Conditions

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

Explore related trials

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-TypeSolid Neoplasm

NCT05046080

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • M D Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Anasis Malpica · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Anasis Malpica
[email protected]
713-792-4655
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients diagnosed with clear cell carcinoma of the cervix at MDACC

What this trial measures

  • Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervixthrough study completion, an average of 1 year